FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHA
Instruction 1(b).	Filed pursuant to Section

NGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Sachdev Amit						2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								(Check all ap		olicable)		ssuer Owner (specify
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE					02/	3. Date of Earliest Transaction (Month/Day/Year) 02/18/2015								X	belo EV	w) (7P, Policy, <i>F</i>	below Access & Val	ue
(Street) BOSTON MA 02210 (City) (State) (Zip)			- 4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line) X	ridual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tabl	e I - I	Non-Deriv	ative	Sec	uritie	s A	cquir	ed, D	isposed c	of, or E	Benefic	ially	Own	ed		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye				Execution Date,			3. Transa Code (8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			5) Secu Bene		ficially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) or (D)	Price		Trans	action(s) 3 and 4)		(instr. 4)	
Common Stock 02/18/201				15	5			S ⁽¹⁾		2,800	D	\$112.6	2 ⁽²⁾⁽³⁾		93,121	D		
Common Stock 02/18/20				15	5			S ⁽¹⁾		3,137	D	\$113.1	4 ⁽³⁾⁽⁴⁾		39,984	D		
Common Stock														882	I	401(k)		
		Та	ble I								posed of, convertib				vned			
1. Title of Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security Date (Month/Day/Year) Execution Date, if any (Month/Day/Yea			4. Transa Code 8)	(Instr.	of Deriv Secu Acqu (A) of Dispo	rities ired r osed) : 3, 4	Expii (Mon	ration I hth/Day	Expiration	Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of		Deri Secu (Inst	Price of erivative ecurity nstr. 5) Securities Beneficially Owned Following Reported Transaction (Instr. 4)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

Explanation of Responses:

- $1.\ Transaction\ made\ pursuant\ to\ Mr.\ Sachdev's\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1.$
- 2. Open market sales reported on this line occurred at a weighted average price of \$112.62 (range \$111.94 to \$112.91).
- 3. Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Open market sales reported on this line occurred at a weighted average price of \$113.14 (range \$112.95 to \$113.78).

Remarks:

Omar White, Attorney-In-Fact 02/20/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.